Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III
About Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
4
University of Heidelberg Medical Center
2
Universität des Saarlandes
2
GWT-TUD GmbH
1
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
1
Onco Medical Consult GmbH
1
RWTH Aachen University
1
Technische Universität Dresden
1
University of Jena
1
University of Ulm
1
Clinical Trials at Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III
During the past decade, Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 3 clinical trials were completed, i.e. on
average, 30% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
2011-07-06
2021-07-30
Completed
1,401
OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
2011-11-01
2024-05-01
Active, not recruiting
1,152
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
2012-08-24
2022-05-31
Completed
717
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML
2013-03-13
2019-10-30
Completed
18
VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MDS AND THROMBOCYTOPENIA
2015-06-01
2021-05-20
Completed
75
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
2014-10-01
2019-05-01
Completed
223
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
2015-06-01
2021-06-24
Completed
564
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
2015-12-30
2020-04-24
Terminated
447
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "University of Heidelberg Medical Center" with 2 trials
sponsored, "Universität des Saarlandes" with 2 trials sponsored, "GWT-TUD GmbH" with 1 trials sponsored and "Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH"
with 1 trials sponsored. Other sponsors include 0 different institutions and
companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III"
#1 collaborator was "Novartis Pharmaceuticals" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Celltrion Healthcare Co., LTD" with 1 trials as a collaborator, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials as a collaborator and "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were
collaborators in the rest 12 trials.
Clinical Trials Conditions at Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III
According to Clinical.Site data, the most researched conditions in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" are
"Multiple Myeloma" (2 trials), "Acute Myeloid Leukemia" (1 trials), "Acute Myeloid Leukemia (AML)" (1 trials), "Advanced Follicular Lymphoma" (1 trials) and "CD20+ Aggressive B-Cell Lymphoma" (1 trials). Many other conditions were trialed in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" in a lesser frequency.
Clinical Trials Intervention Types at Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III
Most popular intervention types in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" are "Drug" (14 trials), "Other" (2 trials), "Device" (1 trials), "Genetic" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Rituximab" (4 trials), "Lenalidomide" (3 trials), "Bendamustine" (2 trials), "Bortezomib" (2 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III
The vast majority of trials in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III" are
15 trials for "All" genders.
Clinical Trials Status at Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III
Currently, there are NaN active trials in "Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III".
undefined are not yet recruiting,
3 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 7 completed trials in Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III, 0 "Phase 1"
clinical trials were conducted, 5 "Phase 2" clinical
trials and 8 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 1 trials that are defined as “Not Applicable".